综合血管扩张策略对急性心衰患者死亡率及再住院的影响:GALACTIC随机临床试验
GALACTIC试验在788例急性心衰患者中比较早期强化持续血管扩张策略与常规治疗,主要终点为180天全因死亡或心衰再住院复合终点。干预组30.6% vs 常规组27.8%(绝对差2.8%,95%CI -3.7%至9.3%;校正HR 1.07,95%CI 0.83-1.39;
要点
- 早期强化持续血管扩张未降低180天全因死亡或心衰再住院风险。
- 干预组头痛、头晕和低血压发生率高于常规治疗组。
- 该策略不推荐用于计划入住普通病房的急性心衰患者。
核心结论
- 在急性心衰患者中,与常规治疗相比,早期强化持续血管扩张策略未显著改善180天全因死亡和心衰再住院复合结局。
研究设计与样本
- 随机、开放标签、盲法终点试验,纳入788例因急性心衰住院患者,来自瑞士、保加利亚、德国、巴西和西班牙的10家三级和二级医院。
- 患者1:1随机至早期强化持续血管扩张策略组(n=386)或常规治疗组(n=402)。
- 781例(99.1%)完成试验并纳入主要终点分析;中位年龄78岁,女性36.9%。
主要发现
- 主要终点(180天全因死亡或心衰再住院复合终点)干预组117例(30.6%),常规组111例(27.8%)。
- 干预组死亡55例(14.4%),常规组死亡61例(15.3%)。
- 常见临床显著不良事件:低钾血症(23% vs 25%)、肾功能恶化(21% vs 20%)、头痛(26% vs 10%)、头晕(15% vs 10%)、低血压(8% vs 2%)。
关键数值与推荐
- 纳入标准:因急性心衰住院伴呼吸困难、利钠肽血浆浓度升高、收缩压至少100 mm Hg,且计划在普通病房治疗。
- 干预策略:个体化剂量舌下和透皮硝酸酯类、低剂量口服肼屈嗪48小时,以及快速上调ACEI、ARB或沙库巴曲缬沙坦。
临床怎么用
- 对于计划入住普通病房的急性心衰患者,早期强化持续血管扩张策略未显示优于常规治疗,不推荐常规采用。
- 应用该策略时需关注头痛、头晕和低血压等不良事件。
局限性
- 开放标签设计可能引入偏倚,但采用盲法终点评估。
- 结果外推需谨慎,仅适用于符合纳入标准的急性心衰患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Short-term infusions of single vasodilators, usually given in a fixed dose, have not improved outcomes in patients with acute heart failure (AHF). OBJECTIVE: To evaluate the effect of a strategy that emphasized early intensive and sustained vasodilation using individualized up-titrated doses of established vasodilators in patients with AHF. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label blinded-end-point trial enrolling 788 patients hospitalized for AHF with dyspnea, increased plasma concentrations of natriuretic peptides, systolic blood pressure of at least 100 mm Hg, and plan for treatment in a general ward in 10 tertiary and secondary hospitals in Switzerland, Bulgaria, Germany, Brazil, and Spain. Enrollment began in December 2007 and follow-up was completed in February 2019. INTERVENTIONS: Patients were randomized 1:1 to a strategy of early intensive and sustained vasodilation throughout the hospitalization (n = 386) or usual care (n = 402). Early intensive and sustained vasodilation was a comprehensive pragmatic approach of maximal and sustained vasodilation combining individualized doses of sublingual and transdermal nitrates, low-dose oral hydralazine for 48 hours, and rapid up-titration of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or sacubitril-valsartan. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of all-cause mortality or rehospitalization for AHF at 180 days. RESULTS: Among 788 patients randomized, 781 (99.1%; median age, 78 years; 36.9% women) completed the trial and were eligible for primary end point analysis. Follow-up at 180 days was completed for 779 patients (99.7%). The primary end point, a composite of all-cause mortality or rehospitalization for AHF at 180 days, occurred in 117 patients (30.6%) in the intervention group (including 55 deaths [14.4%]) and in 111 patients (27.8%) in the usual care group (including 61 deaths [15.3%]) (absolute difference for the primary end point, 2.8% [95% CI, -3.7% to 9.3%]; adjusted hazard ratio, 1.07 [95% CI, 0.83-1.39]; P = .59). The most common clinically significant adverse events with early intensive and sustained vasodilation vs usual care were hypokalemia (23% vs 25%), worsening renal function (21% vs 20%), headache (26% vs 10%), dizziness (15% vs 10%), and hypotension (8% vs 2%). CONCLUSIONS AND RELEVANCE: Among patients with AHF, a strategy of early intensive and sustained vasodilation, compared with usual care, did not significantly improve a composite outcome of all-cause mortality and AHF rehospitalization at 180 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00512759.
引用
- Kozhuharov N, Goudev A, Flores D, et al. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. JAMA. 2019. PMID: 31846016. doi:10.1001/jama.2019.18598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。